Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | EBP | Q15125 | 1/20 | 0.37 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462439 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL14816136 | 0.91 | KDM4E (0.47) | SMN1; SMN2ALDH1A1KDM4EPOLBPKM | |
| SCHEMBL15462505 | 0.91 | KDM4E (0.47) | SMN1; SMN2ALDH1A1KDM4EPOLBPKM | |
| SCHEMBL15462489 | 0.91 | MEN1 (0.43) | LMNAKMT2AMEN1 | |
| SCHEMBL14815396 | 0.91 | MEN1 (0.43) | LMNAKMT2AMEN1 | |
| SCHEMBL15462445 | 0.90 | CNR1 (0.37) | SMN1; SMN2LMNAKMT2APOLBMEN1 | |
| SCHEMBL14816148 | 0.90 | CNR1 (0.37) | SMN1; SMN2LMNAKMT2APOLBMEN1 | |
| SCHEMBL14815402 | 0.90 | MAPT (0.39) | ALDH1A1KDM4ELMNAKMT2APKM | |
| SCHEMBL15462523 | 0.90 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL14816193 | 0.90 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1KDM4ELMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8648074-B2 | Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085141-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1D, CACNA1A | SMN1; SMN2 1986/4885ALDH1A1 1439/4885KDM4E 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.